Pink Sheet Podcast Special: Why The US Approves Most New Drugs Before The EU

 
• By Pink Sheet Team

Pink Sheet reporter and editors discuss the impact of a US and EU drug approvals analysis that found the US FDA still clears many novel products first, including most new cell and gene therapies and cancer treatments.

Pink Sheet podcast
Why has the EU only approved three of the 10 cell and gene therapies approved in the US? • Source: Citeline/Shutterstock

More from Regional Comparisons

More from Pink Sheet